Explore the vast range of titles available.

In migratory species, the temporal phases of the annual cycle are linked to seasonally shifting geographic ranges. Despite intense interest in the annual cycle ecology of migratory species, a synthetic understanding of the relationship between the biogeography of the migratory annual cycle and its phenology remains elusive. Here, we investigate the spatiotemporal structure of the annual cycle in a phylogenetic comparative framework by developing a method to demarcate the pacing of annual cycle stages using eBird, a massive avian occurrence dataset, and applying it to migratory passerine birds breeding in North America. Our analyses reveal a striking negative correlation between the durations of the breeding versus nonbreeding periods, indicating that a tradeoff between the lengths of the two stationary periods is the primary axis of variation in annual cycle pacing. Our results further show that the duration of annual occupancy in the breeding versus stationary nonbreeding ranges predicts the geographic separation of these seasonal ranges, demonstrating that the ratio of time spent on stationary breeding versus nonbreeding locations evolves in tandem with a species' migration distance. In contrast, the amount of time during which species undergo seasonal migration—that is, the duration of the seasonal periods when species' geographic ranges shift latitudinally—varies relatively little across species compared with the length of the stationary periods. Our study helps untangle the complexity of seasonal distributions and schedules to reveal the integrated evolution of the biogeography of the migratory cycle, its pacing, and life history tradeoffs among species.

Common names of species are important for communicating with the general public. In principle, these names should provide an accessible way to engage with and identify species. The common names of species have historically been labile without standard guidelines, even within a language. Currently, there is no systematic assessment of how often common names communicate identifiable and biologically relevant characteristics about species. This is a salient issue in ornithology, where common names are used more often than scientific names for species of birds in written and spoken English, even by professional researchers. To gain a better understanding of the types of terminology used in the English-language common names of bird species, a group of 85 professional ornithologists and non-professional contributors classified unique descriptors in the common names of all recognized species of birds. In the AvianLexiconAtlas database produced by this work, each species’ common name is assigned to one of ten categories associated with aspects of avian biology, ecology, or human culture. Across 10,906 species of birds, 89% have names describing the biology of the species, while the remaining 11% of species have names derived from human cultural references, human names, or local non-English languages. Species with common names based on features of avian biology are more likely to be related to each other or be from the same geographic region. The crowdsourced data collection also revealed that many common names contain specialized or historic terminology unknown to many of the data collectors, and we include these terms in a glossary and gazetteer alongside the dataset. The AvianLexiconAtlas can be used as a quantitative resource to assess the state of terminology in English-language common names of birds. Future research using the database can shed light on historical approaches to nomenclature and how people engage with species through their names.

The prohibition of many drugs has led to the development and implementation of drug related education programs that typically exist at the elementary school level. As many of these programs are funded by the Canadian government, it is possible that such education serves as a means of re-enforcing the traditionally held values that are currently reflected in Canadian drug laws. One alternative form of drug education (DE) occurs at the post-secondary level. The present research examines an alternative form of DE through interviewing four students who attended the University of Ontario Institute of Technology (UOIT) –two who had taken the 4th level course, Advanced Justice Studies: Drugs and Society Course, and two who had not. This thesis determines if the students’ views on drug use, drug users, and drug policies differed. There is some differentiation that occurs between those interviewed; however, this differentiation is not solely attributable to having followed the drug course in question.

In migratory species, the temporal phases of the annual cycle are intrinsically linked to seasonally shifting geographic ranges. Despite intense interest in the annual cycle ecology of migration, a synthetic understanding of the relationship between the biogeography and phenology of seasonal migration remains elusive. Here, we interrogate the spatiotemporal structure of the annual cycle in a novel phylogenetic comparative framework. We use eBird, a massive avian occurrence dataset, to demarcate and measure in a consistent manner among species the portions of the annual cycle when a geographic distribution is stationary versus dynamic due to migration. Through comparative analyses of the durations of annual cycle stages for 150 species of migratory birds breeding in North America, we show that the duration of the migratory periods is remarkably consistent among species and is unrelated to the distance between breeding and nonbreeding locations. In other words, the seasonal distributions of long-distance migrants shift between their geographically distant stationary phases in the same amount of time as short-distance migrants, suggesting that individuals of long-distance migratory species have more synchronous periods of migration and likely a faster individual migratory pace than short-distance migrants. Our results further show that the amount of time a species spends on the breeding grounds is strongly inversely related to time spent on the nonbreeding grounds, revealing the length of the breeding versus nonbreeding stationary period to be the primary source of species-level variation in the pacing of the annual cycle, as opposed to the time needed for the migratory period. Further, our study reveals that the amount of time spent annually on the breeding versus nonbreeding grounds predicts the distance between breeding and nonbreeding locations, demonstrating key linkages between the biogeography of the migratory cycle, its phenology, and the evolution of life history tradeoffs.

Common names of species are important for communicating with the general public. In principle, these names should provide an accessible way to engage with and identify species. The common names of species have historically been labile without standard guidelines, even within a language. Currently, there is no systematic assessment of how often common names communicate identifiable and biologically relevant characteristics about species. This is a particular issue in ornithology, where common names are used more often than scientific names for species of birds in written and spoken English, even by professional researchers. To gain a better understanding of the types of terminology used in the common names of bird species and their frequency of use, we used a crowdsourcing approach and recruited 85 professional ornithologists and non-professional participants to classify unique descriptors in the English-language common names of all recognized bird species from around the world. Each species' common name was assigned to one of ten categories associated with aspects of avian biology, ecology, or human culture. Across 10,906 species of birds, 89% have names describing the biology of the species, while the remaining 11% of species have names derived from human cultural references or local non-English languages. Species with common names based on features of avian biology are more likely to be related to each other or be from the same geographic region. The crowdsourced data collection also revealed that many common names contained specialized or historic terminology unknown to many of the data collectors, and this was documented in a glossary and gazetteer alongside the dataset. As the first comprehensive assessment of the state of terminology in English-language common names of birds, the AvianLexiconAtlas database sheds light on historical approaches to nomenclature and provides insight into how the general public currently engages with species through their names.Competing Interest StatementThe authors have declared no competing interest.Footnotes* The title, abstract, introduction, and conclusion have been updated to present the new dataset, glossary, and gazetteer produced during this research as a research database, now called the AvianLexiconAtlas. Researchers from across academic fields can use the resources in this database to study the history of English-language bird names from a quantitative perspective. In the text we clarify the utility of this database as a resource, but have not changed any of the methods, analyses, figures, or supplemental files.* https://github.com/ajshultz/AvianLexiconAtlas

PD-L1 and VEGF blockade with atezolizumab plus bevacizumab has been shown to improve survival in unresectable hepatocellular carcinoma. TIGIT is an immune checkpoint regulator implicated in many cancers, including unresectable hepatocellular carcinoma. Here, we evaluate the clinical activity and safety of the addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab plus bevacizumab. This randomised, open-label, phase 1b–2 umbrella study was conducted at 26 centres across China, France, Israel, New Zealand, South Korea, Taiwan, and the USA. Eligible patients were adults aged 18 years old or older with previously untreated locally advanced unresectable hepatocellular carcinoma, an Eastern Cooperative Oncology Group performance status of 0–1, Child-Pugh class A disease, and a life expectancy of at least 3 months. Eligible patients were randomly assigned (2:1) using permuted block randomisation to receive either tiragolumab 600 mg plus atezolizumab 1200 mg plus bevacizumab 15 mg/kg or atezolizumab 1200 mg plus bevacizumab 15 mg/kg, administered via intravenous infusion every 3 weeks on day 1 of each 21-day cycle. Patients received treatment until unacceptable toxic effects or loss of clinical benefit, whichever occurred first. The primary endpoint was objective response rate. Analysis of clinical activity was done in the efficacy-evaluable population (all patients who received at least one dose of each drug for their assigned treatment regimen) and safety was assessed in all patients who received any study treatment. The trial is registered with ClinicalTrials.gov, NCT04524871, and is ongoing. Between Aug 20, 2020, and Feb 10, 2022, we assessed 154 patients for eligibility and 59 eligible patients were randomly assigned to receive tiragolumab plus atezolizumab plus bevacizumab (n=41) or atezolizumab plus bevacizumab (n=18); one patient in the tiragolumab plus atezolizumab plus bevacizumab group experienced an adverse event before receiving any treatment and withdrew from the study. Median age was 65·0 years (IQR 61·0–73·0). 46 (79%) of 58 patients were male and 12 (21%) were female. Most patients were Asian (23 [40%]) or White (21 [36%]). At the time of clinical cutoff (Aug 21, 2023), median follow-up was 20·6 months (IQR 10·6–28·0) in the tiragolumab plus atezolizumab plus bevacizumab group and 14·0 months (4·2–18·5) in the atezolizumab plus bevacizumab group. The confirmed objective response rate was 43% (95% CI 27–59, n=17) in the tiragolumab plus atezolizumab plus bevacizumab group and 11% (1–35, n=2) in the atezolizumab plus bevacizumab group. All patients in both groups experienced an adverse event. The incidence of pruritis (20 [50%] of 40 patients vs three [17%] of 18 patients), arthralgia (13 [33%] vs two [11%]), and diarrhoea (12 [30%] vs one [6%]) was notably higher in the tiragolumab plus atezolizumab plus bevacizumab group than in the atezolizumab plus bevacizumab group, although these were mainly grade 1–2. The most common grade 3–4 adverse events were hypertension (six [15%] of 40 patients in the tiragolumab plus atezolizumab plus bevacizumab group vs two [11%] of 18 patients in the atezolizumab plus bevacizumab group), aspartate aminotransferase increased (three [8%] of 40 patients vs one [6%] of 18 patients), and proteinuria (two [5%] of 40 patients vs two [11%] of 18 patients). Serious adverse events occurred in 21 (53%) of 40 patients in the tiragolumab plus atezolizumab plus bevacizumab group and in ten (56%) of 18 patients in the atezolizumab plus bevacizumab group. Treatment-related deaths occurred in one patient in the tiragolumab plus atezolizumab plus bevacizumab group (due to cholestasis) and two patients in the atezolizumab plus bevacizumab group (due to oesophageal varices haemorrhage and upper gastrointestinal haemorrhage). The addition of tiragolumab to atezolizumab plus bevacizumab did not appear to result in a substantial worsening of treatment-related or immune-mediated adverse events, and no new safety signals were identified. This signal-seeking study suggests that the addition of tiragolumab to atezolizumab and bevacizumab might be more clinically active than atezolizumab plus bevacizumab alone in unresectable hepatocellular carcinoma. Based on these data, further study of combination tiragolumab plus atezolizumab plus bevacizumab is warranted. F Hoffmann-La Roche and Genentech.